(Reuters) - Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional bulk product and the final freeze-dried doses of its mpox and smallpox vaccine, Jynneos, it said on Tuesday.

Bavarian Nordic has received a $63 million order from BARDA to produce Jynneos mpox vaccine doses. The contract will support the manufacturing of 1 million freeze-dried vaccines, set for delivery by 2026,

With the outbreak of Mpox in several countries, the demand for vaccines has increased. The vaccine, administered as a 2-dose injection given 4 weeks apart was the first jab against Mpox to be prequalified by the World Health Organization (WHO).

The World Health Organization and partners on Friday set up a scheme to help bring mpox vaccines, tests and treatments to the most vulnerable people in the world’s poorest countries, similar to efforts during the COVID-19 pandemic,

Research shows that the effectiveness of Bavarian Nordic’s Mpox vaccine drops to undetectable levels after 6-12 months.

Gavi, the global vaccine group, announced it will purchase 500,000 doses of Bavarian Nordic’s mpox vaccine. This marks Gavi’s first acquisition of the vaccine to aid in combating an outbreak in parts of Africa.

The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to help battle an outbreak in parts of Africa, the group said on Wednesday.

The escalating global Mpox outbreak has been met with a concerning revelation. Two distinct studies have indicated that the efficacy of Bavarian Nordic's vaccine, known as Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN),

Two recent studies reveal that the efficacy of Bavarian Nordic's Mpox vaccine significantly declines within 6-12 months post-vaccination.